Anti-SARS-CoV-2 immunoglobulin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Anti-SARS-CoV-2 immunoglobulin
Accession Number
DB16360
Description

Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is obtained from the plasma of patients who recover from COVID-19 and develop neutralizing antibodies.1 Anti-coronavirus immunoglobulin is derived from COVID-19 convalescent plasma but contains more SARS-CoV-2 neutralizing antibodies than found in convalescent plasma as the antibodies are highly purified and concentrated.1,2

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Polyclonal antibody (pAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Anti-Coronavirus immunoglobulin
  • Anti-COVID-19 hyperimmune globulin (human)
  • GC5131
  • hIVIG
  • Human plasma-derived immune-globulin for Coronavirus
  • Hyperimmune immunoglobulin to SARS-CoV-2
  • Immune-globulin for Coronavirus disease (COVID-19)
External IDs
  • Anti-SARS-CoV-2 immunoglobulin

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. ClinicalTrials.gov: IInpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC) [Link]
  2. European Pharmaceutical Review: Trial testing anti-coronavirus hIVIG plus remdesivir in COVID-19 patients [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentInfluenza A Virus Infection / Influenza Type B1
3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID / COVID - 19 / SARS (Severe Acute Respiratory Syndrome)1
2RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
1, 2Not Yet RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
1, 2RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Viral Pneumonia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 17, 2020 10:42 / Updated on January 01, 2021 00:43

Ddi 5